A new study by researchers at Children’s Hospital of Philadelphia (CHOP) shows that linking a tumor-killing prodrug to a macromolecular carrier of the Poloxamer family improves retention of the drug in treatment-resistant neuroblastoma tumors, leading to rapid tumor regression and lasting therapeutic responses in several preclinical models. The findings were recently published in The Federation of American Societies for Experimental Biology Journal.